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Why was it important to do this Cochrane review?
One in 11 children in the UK, and elsewhere in the western world, suffer from asthma. Morbidity 
and mortality associated with childhood asthma continues to increase and yet evidence specifically 
relating to asthma treatments in paediatric populations remains scarce. Prompt treatment of acute 
asthma in the emergency setting is important to avoid rising asthma-related hospital stays, intensive 
care admissions (Nyman 2011), and deaths (NRAD 2014). 
An earlier version of this Cochrane review published in 2000 included seven studies (5 adult 2 
paediatric studies) and found little evidence to support the use of intravenous magnesium sulfate (IV 
MgSO4) in children. Despite this, national and international treatment guidelines continued to 
advocate the use of IV MgSO4 in the treatment of acute asthma in children who have not responded 
to first-line treatment (bronchodilators and steroids) (BTS/SIGN 2014; GINA 2015). 
It was possible that subsequent research published over the subsequent sixteen years had the 
potential to impact the conclusions for both adults and children. We split the review update into 
child and adult populations, allowing us to explore more easily effect modifiers within each age 
group. The adult review included 14 studies (N=2313) and found IV MgSO4 reduced the need for 
hospital admission compared with placebo (Kew 2014), posing an important question of whether the 
same was true for children. 
What were the objectives of the review?
The main aim of the review was to assess whether giving IV MgSO4 for acute asthma in the ED 
reduces the need for admission to hospital. Secondary aims were to evaluate adverse events and 
whether the treatment has additional benefits including reducing the time spent in the ED or the 
need for intensive care.
What was the evidence base of the review?
Only five studies met all the inclusion criteria (Ciarallo 1996; Ciarallo 2000; Devi 1997; Gürkan 1999; 
Scarfone 2000), randomising a total of 182 children presenting to the ED: 89 to receive MgSO4 and 
93 to receive a matching placebo infusion of saline. Sample sizes were small, ranging from 20 to 54, 
meaning that although the studies were mostly at low risk of bias, our confidence in the evidence 
was generally low because the results were based on so few children.
As per the pre-defined inclusion criteria, all studies were randomised, double-blind, placebo-
controlled trials. Populations, interventions and procedures varied across the five studies with 
respect to age, severity of exacerbation, allowed and disallowed co-medications, and characteristics 
of the intervention (Table 1). The main measurements were taken between 90 and 120 minutes 
after the start of the magnesium infusion. Children included in the studies had predominantly 
moderate to severe acute asthma and had mostly received nebulised bronchodilators, IV 
corticosteroids and oxygen before randomisation.
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Classification of asthma severity is widely reported in research but in paediatric practice is more 
problematic due to the difficulty in obtaining spirometry in the emergency setting.  In the review, 
studies were classified according to their inclusion criteria and the available baseline characteristics 
of the children recruited (such as respiratory and heart rate, peak flow etc.), in the hope of 
identifying subgroups of children who are most likely to benefit. However due to the small number 
of studies and included children teasing out severity response was not possible. 
What were the findings of the review?  Overall, there was a striking paucity of data, especially with 
regard to the secondary outcomes (ED treatment duration, intensive care admissions, hospital 
length of stay, vital signs, spirometry, symptom scores and adverse events).
Admission to hospital was the primary outcome, and analysis of three studies showed the odds were 
68% lower in the children given IV MgSO4 than those given a placebo infusion (OR 0.32, 95% CI 0.14 
to 0.74; fixed-effects). While this is a large reduction, it should be interpreted with caution due to 
the small number of children in the analysis (n = 115) and variation between the individual study 
results (see Figure 1). It is difficult to explore what caused this variation with so few studies, but their 
designs and populations were broadly comparable (Table 1). Performing a sensitivity analysis of the 
same admission data using a random-effects model gave a rather different result (OR 0.18, 95% CI 
0.02 to 1.59; random effects) that did not reach statistical significance.  
Nothing can be said of the effect of IV MgSO4 on intensive care admissions, vital signs, spirometry, or 
scores on symptom scales, and there was very limited data about the likelihood of returning to the 
ED within 48 hours. Some of the studies narratively reported benefits on lung function and symptom 
scales, but we found little numerical data. Reported side-effects were generally mild and infrequent, 
but it is difficult to know whether this is evidence of safety or a consequence of incomplete or 
inconsistent recording and small sample sizes.
What are the implications of this review for practice and for research?
This review provides very weak vidence to support the use of IV MgSO4 in the treatment of asthma 
in children who have not responded to first line treatment. The result favouring the use of IV MgSO4
to reduce hospital admissions is in keeping with the adult review and other non randomised studies 
including children. However, due to the small study sizes and degree of heterogeneity we have put 
less confidence in our findings than the adult review.
The weak evidence favouring reduced hospital admissions combined with the likelihood of minimal 
harm suggests it is still a reasonable treatment option. However, as data are scarce and there have 
been few RCTs published in recent years, equipoise still exists. Further studies would help answer 
the question with more certainty and identify subgroups of children who may benefit most from this 
treatment. Trialists should clearly document severity, focusing on important clinical outcomes that 
can further inform clinicians and future guidance on IV magnesium infusions in children with acute 
asthma in the emergency department. 
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Table1. Summary of studies included in the review
ID
Country 
(centres) N
Age range 
(mean y)
Inclusion % PEF MgSO4
infusion Co-treatments
Ciarallo 1996 USA (2) 30 6 to 18
(11.4)
PEF < 60% predicted after 3 beta2-
adrenergic nebuliser treatments
43.4 25 mg/kg
20 mins
3 nebulised bronchodilators (albuterol, ipratropium 
bromide, or both)
IV methylprednisolone (2 mg/kg) if not yet given 
corticosteroids
Ciarallo 2000 USA (1) 31 6 to 18
(11.4)
PEF < 70% predicted
(after 3 nebulised bronchodilator 
treatments)
31.4 40 mg/kg
20 mins
3 nebulised beta-2 adrenergic treatments
IV methylprednisolone (2 mg/kg) if not yet given 
corticosteroids
Devi 1997 India (1) 47 1 to 12
(6.7)
"Inadequate or poor response to 3 
doses of nebulized salbutamol"
28.6 0.2 ml of 50%
35 mins
Nebulised salbutamol
Oxygen, IV aminophylline, corticosteroids
Gürkan 1999 Turkey (1) 20 6 to 16
(10.8)
PEF < 60% predicted
(after 3 beta-2 adrenergic 
nebuliser treatments)
46.5 40 mg/kg
20 mins
3 beta-2 adrenergic nebuliser treatments
Scarfone 2000 USA (3) 54 1 to 18
(5.7)
"moderate to severe asthma 
exacerbation"
NR 75 mg/kg
20 mins
Nebulised albuterol
Oxygen, methylprednisolone
Figure 1. Forest plot showing the effect of intravenous magnesium on hospital admissions compared with a placebo infusion.
